Opticon delays launch of clinical trial:
This article was originally published in Clinica
Opticon Medical has delayed a pivotal clinical trial of its urinary catheter, the Option-vf, in order to implement an "engineering change" to a feature of the device, says the company. Opticon president William Post said that the delay in patient enrolment in exchange for the latest technology is "worth the trade off". Last year, the Dublin, Ohio-based company reported promising results from a pilot study of the Option-vf, which is designed for the short-term management of urinary retention following lower urinary tract surgery (see Clinica No 923, p 17).
You may also be interested in...
Europe's largest online pharmacy is calling for online sales of OTC medicines to be allowed in its home market Switzerland, to increase the supply of crucial products to help people manage the symptoms of COVID-19, such as headaches, fever, diarrhoea, coughs, colds or nausea.
Confusion is rife over low UK testing levels to confirm COVID-19 in health care staff and patients, and comparisons with measures taken in similar-sized economies have been unfavorable. Diagnostics manufacturers are not to blame, says the industry.
Novartis's Jakavi joins the likes of Roche's Actemra in targeting the life-threatening immune reaction which is killing acutely ill COVID-19 patients.